[{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acura Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Healthcare Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AFT Pharmaceuticals \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Immunology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Remedies \/ Not Applicable"},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alter Pharma group \/ Hyloris","highestDevelopmentStatusID":"12","companyTruncated":"Alter Pharma group \/ Hyloris"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharma, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharma, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharma, LLC"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"MHRA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reckitt Benckiser \/ MHRA","highestDevelopmentStatusID":"12","companyTruncated":"Reckitt Benckiser \/ MHRA"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Evolution Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Evolution Research Group"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ University of Rochester Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Seton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Seton Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ Not Applicable"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Gabapentin","moa":"CaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Nevakar","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ Endo International"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Salus Pharmaceuticals \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ Lavipharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ Lavipharm"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vocacapsaicin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Concentric Analgesics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Concentric Analgesics \/ Not Applicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elite Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Minoset
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
FAMAR CDMO- From early development to commercial manufacturing.
